Yu, Shengyuan
Ran, Ye
Xiao, Wei
Tang, Wenjing
Zhao, Jianjun
Chen, Wei
Zhuang, Huikui
Ouyang, Cun
Lin, Hai
Liu, Dequan
Chen, Tongjun
Huang, Hui
Wang, Baoshen
Hao, Yanlei
Yan, Zhongrui
Zhao, Shike
Wang, Yanling
Ni, Jinjun
Wang, Chaodong
Ding, Wentao
Li, Guoqian
Cao, Jianhua
Tian, Shujuan
Funding for this research was provided by:
National Scientific Research Fund of China (81671077)
Beijing Science and Technology Project (Z161100002616013)
“One Hundred Advantage Projects” Fund of Chinese PLA General Hospital (YS201414)
Article History
Received: 29 September 2017
Accepted: 27 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: Clearance for the trial was obtained from the Ethical Committee of the Chinese PLA General Hospital, and the authorized document number is C2013–066-01. All participants provided written informed consent to participate in our study.
: All participants provided written informed consent for publication.
: Author Dr. Wei Xiao hold shares in Kanion Pharmaceutical Company. Other authors declare that they have no competing interests. Kanion Pharmaceutical Company manufactured the intervention products for the study. However, Kanion Pharmaceutical Company had no role in the design, implementation, analysis, or publication of the trial.